Kaleb Yohay

3.1k total citations
34 papers, 948 citations indexed

About

Kaleb Yohay is a scholar working on Neurology, Epidemiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Kaleb Yohay has authored 34 papers receiving a total of 948 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Neurology, 12 papers in Epidemiology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Kaleb Yohay's work include Neurofibromatosis and Schwannoma Cases (19 papers), Meningioma and schwannoma management (11 papers) and Sarcoma Diagnosis and Treatment (5 papers). Kaleb Yohay is often cited by papers focused on Neurofibromatosis and Schwannoma Cases (19 papers), Meningioma and schwannoma management (11 papers) and Sarcoma Diagnosis and Treatment (5 papers). Kaleb Yohay collaborates with scholars based in United States, Australia and Italy. Kaleb Yohay's co-authors include David S. Vicario, Bruce R. Korf, Katherine L. Nathanson, Douglas R. Stewart, David A. Stevenson, Barry E. Kosofsky, Ronald G. Crystal, Arturo Álvarez-Buylla, Fernando Nottebohm and Dolan Sondhi and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Genes & Development.

In The Last Decade

Kaleb Yohay

30 papers receiving 928 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kaleb Yohay United States 16 320 179 173 158 151 34 948
Kaveh Barami United States 19 266 0.8× 27 0.2× 386 2.2× 165 1.0× 148 1.0× 38 1.3k
István Sziklai Hungary 26 145 0.5× 100 0.6× 335 1.9× 23 0.1× 141 0.9× 88 1.7k
Elizabeth M. Thompson United Kingdom 26 146 0.5× 77 0.4× 672 3.9× 17 0.1× 123 0.8× 67 1.7k
Rick A. Friedman United States 25 137 0.4× 55 0.3× 661 3.8× 28 0.2× 51 0.3× 53 1.7k
Christine E. Thomson United Kingdom 20 166 0.5× 118 0.7× 579 3.3× 13 0.1× 37 0.2× 35 1.7k
Tomoyuki Hoshino Japan 19 179 0.6× 262 1.5× 208 1.2× 9 0.1× 181 1.2× 100 1.5k
Ronna Hertzano United States 27 170 0.5× 87 0.5× 739 4.3× 20 0.1× 57 0.4× 57 2.0k
Kathrin Herrmann Germany 18 19 0.1× 82 0.5× 273 1.6× 154 1.0× 84 0.6× 27 1.1k
Denise Malicki United States 21 167 0.5× 46 0.3× 738 4.3× 13 0.1× 101 0.7× 66 1.7k
Michael R. Bowl United Kingdom 27 105 0.3× 81 0.5× 836 4.8× 11 0.1× 255 1.7× 49 1.9k

Countries citing papers authored by Kaleb Yohay

Since Specialization
Citations

This map shows the geographic impact of Kaleb Yohay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kaleb Yohay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kaleb Yohay more than expected).

Fields of papers citing papers by Kaleb Yohay

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kaleb Yohay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kaleb Yohay. The network helps show where Kaleb Yohay may publish in the future.

Co-authorship network of co-authors of Kaleb Yohay

This figure shows the co-authorship network connecting the top 25 collaborators of Kaleb Yohay. A scholar is included among the top collaborators of Kaleb Yohay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kaleb Yohay. Kaleb Yohay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gutmann, David H., Corina Anastasaki, Aditi Gupta, et al.. (2025). Cognition and behavior in neurofibromatosis type 1: report and perspective from the Cognition and Behavior in NF1 (CABIN) Task Force. Genes & Development. 39(9-10). 541–554. 1 indexed citations
2.
Merker, Vanessa L., Lori B. Chibnik, Heather B. Radtke, et al.. (2025). Self-reported access to specialty clinics and receipt of health surveillance among U.S. patients with neurofibromatosis 1: a national survey. Orphanet Journal of Rare Diseases. 20(1). 185–185.
3.
Yin, Lu, Steven G. Friedman, Devorah Segal, et al.. (2024). Cutaneous Toxicities of MEK Inhibitor Use in Children: A Comparison of Binimetinib and Selumetinib. Pediatric Dermatology. 42(1). 67–72. 1 indexed citations
4.
Yohay, Kaleb, et al.. (2024). Identifying Lesions of the Corpus Callosum in Patients With Neurofibromatosis Type 1. Pediatric Neurology. 156. 66–71.
5.
Neifert, Sean N., David B. Kurland, Nora C. Kim, et al.. (2022). Management and surgical outcomes of dystrophic scoliosis in neurofibromatosis type 1: a systematic review. Neurosurgical FOCUS. 52(5). E7–E7. 6 indexed citations
6.
Banerjee, Jineta, Jan M. Friedman, Laura J. Klesse, et al.. (2022). COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis. Genetics in Medicine. 25(2). 100324–100324.
7.
Merker, Vanessa L., Pamela Knight, Heather B. Radtke, et al.. (2022). Awareness and agreement with neurofibromatosis care guidelines among U.S. neurofibromatosis specialists. Orphanet Journal of Rare Diseases. 17(1). 44–44. 4 indexed citations
8.
Akshintala, Srivandana, Kaleb Yohay, Alona Muzikansky, et al.. (2021). Reliability of Handheld Dynamometry to Measure Focal Muscle Weakness in Neurofibromatosis Types 1 and 2. Neurology. 97(7_Supplement_1). S99–S110. 3 indexed citations
9.
Klesse, Laura J., Justin T. Jordan, Heather B. Radtke, et al.. (2020). The Use of MEK Inhibitors in Neurofibromatosis Type 1–Associated Tumors and Management of Toxicities. The Oncologist. 25(7). e1109–e1116. 65 indexed citations
10.
Hausman‐Kedem, Moran, Barry E. Kosofsky, Gail Ross, et al.. (2018). Accuracy of Reported Community Diagnosis of Autism Spectrum Disorder. Journal of Psychopathology and Behavioral Assessment. 40(3). 367–375. 13 indexed citations
11.
Stewart, Douglas R., Bruce R. Korf, Katherine L. Nathanson, David A. Stevenson, & Kaleb Yohay. (2018). Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine. 20(7). 671–682. 110 indexed citations
12.
Nickel, Miriam, Alessandro Simonati, David Jacoby, et al.. (2018). Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study. The Lancet Child & Adolescent Health. 2(8). 582–590. 89 indexed citations
13.
Dyke, Jonathan P., Dolan Sondhi, Henning U. Voss, et al.. (2016). Brain Region–Specific Degeneration with Disease Progression in Late Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease). American Journal of Neuroradiology. 37(6). 1160–1169. 20 indexed citations
14.
Vargas, Wendy, Linda Heier, Fausto J. Rodríguez, Amanda L. Bergner, & Kaleb Yohay. (2014). Incidental parenchymal magnetic resonance imaging findings in the brains of patients with neurofibromatosis type 2. NeuroImage Clinical. 4. 258–265. 2 indexed citations
15.
Orlin, Anton, Dolan Sondhi, Matthew T. Witmer, et al.. (2013). Spectrum of Ocular Manifestations in CLN2-Associated Batten (Jansky-Bielschowsky) Disease Correlate with Advancing Age and Deteriorating Neurological Function. PLoS ONE. 8(8). e73128–e73128. 32 indexed citations
16.
Sondhi, Dolan, Linda K. Johnson, Keith P. Purpura, et al.. (2012). Long-Term Expression and Safety of Administration of AAVrh.10hCLN2 to the Brain of Rats and Nonhuman Primates for the Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis. Human Gene Therapy Methods. 23(5). 324–335. 79 indexed citations
17.
Yohay, Kaleb. (2006). Neurofibromatosis Types 1 and 2. The Neurologist. 12(2). 86–93. 33 indexed citations
18.
Yohay, Kaleb. (2006). The Genetic and Molecular Pathogenesis of NF1 and NF2. Seminars in Pediatric Neurology. 13(1). 21–26. 50 indexed citations
19.
Adams, David B., et al.. (1993). Offense produced by chemical stimulation of the anterior hypothalamus of the rat. Physiology & Behavior. 53(6). 1127–1132. 33 indexed citations
20.
Vicario, David S. & Kaleb Yohay. (1993). Song‐selective auditory input to a forebrain vocal control nucleus in the zebra finch. Journal of Neurobiology. 24(4). 488–505. 107 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kaveh Barami Breakdown of academic impact, for papers by István Sziklai Breakdown of academic impact, for papers by Elizabeth M. Thompson Breakdown of academic impact, for papers by Rick A. Friedman Breakdown of academic impact, for papers by Christine E. Thomson Breakdown of academic impact, for papers by Tomoyuki Hoshino Breakdown of academic impact, for papers by Ronna Hertzano Breakdown of academic impact, for papers by Kathrin Herrmann Breakdown of academic impact, for papers by Denise Malicki Breakdown of academic impact, for papers by Michael R. Bowl
Rankless by CCL
2026